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Abstract
Background: In populations in which the incidence of hepatitis A virus (HAV) infection has declined due to socio-
economic improvements, better sanitation and hygiene, and vaccination, birth cohorts who have long-term
immunity through exposure early in life are now being replaced by non-immune cohorts, meaning that more cases
in the elderly may occur in future. Our goal was to qualitatively investigate the interaction of this cohort effect and
demographic change (population ageing) on the estimated disease burden of HAV infection in the Netherlands.
Methods: We used dynamic MSIR (maternal immunity–susceptible–infectious–recovered) transmission and
demographic models to simulate annual HAV incidence over the period 2000–2030, and estimated disease burden
using the disability-adjusted life years (DALY) measure and a pre-defined disease progression model. Five scenarios
representing different force of infection situations were simulated.
Results: The overall disease burden was projected to decrease over the simulation period in the baseline scenario
(310 DALYs in 2000 compared with 67 in 2030). This decreasing trend was absent for the 55+ years age group;
23.5% of all new infections were predicted to occur in the 55+ group in 2030, compared with 5.5% in the 55+
group in 2000.
Conclusions: In the absence of further public health interventions and under the assumption of a continued
steady decline in the force of infection, the HAV disease burden in the Netherlands is predicted to decrease over
the coming decades, but with proportionally more of the burden occurring within the increasingly larger segment
of the population represented by elderly persons who are no longer naturally immune.
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Population ageing
Background
In the Netherlands, hepatitis A virus (HAV) infection is
not considered a major public health problem because
of the low incidence of infection; the majority of new in-
fections are observed in defined risk groups such as men
who have sex with men (MSM) and travellers to coun-
tries where HAV is endemic. Due to improved socio-
economic and sanitation conditions since the end of the
Second World War and an increase in vaccine-induced
protection in recent years [1], the force of infection (FOI;
the risk per susceptible person per unit time of becoming
infected) has steadily declined [2-4]. However, the size of
the susceptible population and the likelihood of outbreaks
occurring are expected to increase in the coming decades
because of the cohort effect: younger birth cohorts have
less exposure to HAV, and over time the segment of the
population with natural HAV immunity is being replaced.
Seroprevalence surveys conducted in 1995/6 and 2006/7
showed that 77% of persons in the Netherlands born be-
fore 1945 were anti-HAV positive [1,5], compared with
fewer than 10% born after 1960 [5].
Dynamic demographic processes such as mortality, fer-
tility, and migration that influence the age-distribution
of the population also have an impact on the projected
* Correspondence: scott.mcdonald@rivm.nl
1Centre for Infectious Disease Control, National Institute for Public Health
and the Environment, Bilthoven, The Netherlands
Full list of author information is available at the end of the article
© 2013 McDonald et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
McDonald et al. BMC Infectious Diseases 2013, 13:120
http://www.biomedcentral.com/1471-2334/13/120
number of HAV cases, and consequently the estima-
ted population-level disease burden. Complications from
HAV are more frequent and more severe in adults than in
children [6]; hence, any public health benefit from a de-
creasing trend in the force of infection may be offset by
the increased morbidity and mortality expected with an
older average age at infection.
In the current study we developed a simple determin-
istic sex- and age-structured model of the transmission
dynamics of HAV, integrated with a dynamic model
of demographic change. The transmission model was
needed because exposure is birth cohort-dependent,
under the assumption of a decreasing FOI that is attrib-
utable to improvements in hygiene. We calculated
disease burden based on estimated annual incidence
generated through simulation of HAV transmission over
the period 2000–2030, to assess the interaction between
the diminishing of natural immunity in the population
(i.e., the replacement of immune cohorts) and popula-
tion ageing on the burden of HAV in the Netherlands.
We also compared the predicted burden associated with
each of these two factors alone by removing the other
from the model. Recently, HAV burden has been com-
puted based on current notification data and estimates
of under-reporting/under-ascertainment [7], but fore-
casts have not been made. Our aim was not to precisely
estimate the current or future disease burden, but to
qualitatively investigate the differences in estimated bur-
den under various transmission scenarios.
Methods
Modelling infection dynamics
A sex- and age-structured MSIR (maternal immunity—
susceptible—infectious--recovered) deterministic model
of the infection dynamics of HAV in the Netherlands
population was implemented. In this approach the popu-
lation is stratified into ‘compartments’ according to sex,
1-year age group (<1 years through 85+ years), and sta-
tus (maternal immunity, susceptible, infected/infectious,
recovered/immune) (Figure 1); flow of individuals be-
tween compartments occurs at rates defined by the
model parameters and described by a set of differential
equations. Ageing was modelled by advancing all com-
partments one age group at the end of each simulation
year. The model parameters are: α (the rate of loss of
maternal immunity after birth), λ (the force of infection
(FOI), or the rate that susceptibles become infected),
γ (the rate that infected/infectious persons recover
and develop life-long immunity), b (the birth rate), and
η (the rate of entering/exiting compartments due to
demographic processes)(see Table 1). These processes –
migration, death, and ageing, are described below.
Although the actual HAV situation in the Netherlands is
perhaps best characterised by individual and small
clusters of cases, for convenience we model it as an
endemic disease.
Imported (travel) cases and transmission among MSM
are two important routes of HAV infection. In the period
1993–2002, notification data indicated that 64% of infec-
tions were acquired in the Netherlands, with 18% of infec-
tions acquired in Morocco and Turkey, countries where
HAV is endemic [8]. Incidence rates among travellers to
these countries, particularly children, dropped markedly
between 2000 and 2005 [9], consistent with targetted vac-
cination efforts. Based on these findings, we assumed that
36% of infections were acquired through travel to an en-
demic country. The overall FOI (λa) and domestic trans-
mission rates (βdom,a) were estimated separately for each
age-group (Table 1) by visually fitting the model to the age
distribution of notified cases (national data from OSIRIS;
data and model fit are provided in the Additional file 1:
Figure A2). The transmission rate for travel-acquired
infection (βtrav) was therefore defined as 0.36 λ. The FOI
for domestically acquired infections (64% of total) depends
on the fraction of infectious persons in the population
(see Table 1 for parameter summary).
The rate of recovery from infection (γ) was set at
10.4 year-1, based on an estimated mean duration of infec-
tiousness of 5 weeks [10], and the assumption that this
duration is exponentially distributed.
A large national seroprevalence study in the Netherlands
(Pienter) was conducted in 1995–1996 (n = 7373) [11,12].
M S I R
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Figure 1 Compartmental model for the transmission of hepatitis A, shown for the age group <1 years (for all other age-groups, the
inflows to the M and S compartments due to births are not present). The model is stratified by sex and and by age (1-year age groups,
from <1 years to 85+ years), with ageing simulated by advancing all compartments one age group at the end of each simulation year.
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Sex- and age-group specific seroprevalence from the
Pienter dataset were used as initial values for the recov-
ered/immune model compartment. Vaccination uptake
was assumed to be constant over the time period modeled;
thus it does not impact on transmission dynamics.
Maternal immunity is short-lived, with antibody de-
tected after 1 year in only 39% of babies born HAV
antibody-positive [13]. The parameter Ψ represents the
proportion of babies born with maternally-acquired im-
munity, and was estimated at 13% for males and 17%
for females, based on seroprevalence survey data for
the <1 year age group [11,12]. The rate of loss of mater-
nal immunity was set to 1.33 year-1, derived assuming a
mean duration of 9 months [13].
Modelling demographic dynamics
Dynamic modelling of the Netherlands population was
undertaken for the period 2000–2030, using demo-
graphic information available from Statistics Netherlands
(CBS) for 2000, specifically population size stratified by
sex and 1-year age-group [0 to 85+ years], age- and sex-
specific mortality rates, age-specific fertility rates, and
age-specific net migration rates. Life-table methods were
used to calculate life expectancy for each age-group
from mortality rates, and sex- and age-specific net mi-
gration rates were fixed as the mean net migration over
the period 2000–2009 (see [14] for further details).
The evolution of the age distribution of the popula-
tion over the simulation period was computed using
Leslie matrices [15].
Modelling disease progression
The outcome tree for HAV disease progression was
adopted from that developed as part of the Burden of
Communicable Disease in Europe (BCoDE) project [16].
Although acute HAV infection can lead to complications
and severe sequelae, such as fulminant hepatitis, liver fail-
ure, prolonged cholestasis, and Guillain-Barré syndrome,
such outcomes are very rare and were therefore not incorpo-
rated into the disease progression model (Additional file 1:
Figure A1), similar to Havelaar et al. [7]. Disability
weights and durations were adapted from those com-
piled for the BCoDE project (see Additional file 1: Table
A1 for details), which were based on Havelaar et al. [7].
The greatest risk of mortality from acute HAV infec-
tion is observed in the elderly [17]. We used published
age-specific case-fatality rates to specify mortality follow-
ing acute infection [4,18,19].
DALY computations
To estimate disease burden, we used the pathogen-based
approach, in which all (future) health outcomes causally
related to infection with the pathogen, including acute
infection, are taken into account in the calculation of
the total disease burden [16,20]. We used the disability-
adjusted life-years (DALY) measure [21] which quantifies
the difference, in years, between ideal health and actual
health status associated with illness, disease, or injury.
One DALY corresponds to one lost year of healthy life,
or to multiple years experienced at less than full health.
The DALY measure is the sum of two components:
years of life lost (YLL) due to premature death and years
Table 1 MSIR transmission model parameters, values, and sources
Parameter Value Reference
α – rate of loss of maternal immunity 1/α = 9 months Lieberman et al. [13]
Ψ – proportion of babies born with
maternal immunity
0.13 (males) 0.17 (females) Pienter study (de Melker
et al.[11]; van den Hof
et al.[12])
γ – rate of recovery from infection 1/ γ = 5 weeks Leach [10]
φ – proportion of travel-related cases
(used during fitting only)
0.356 van der Eerden et al. [8]
βdom,a(t) – transmission rate (domestic),
t=2000, for age-groups {<1, 1–4, 5–9, 10–14, 15–19,








λa(t) – force of infection, age-group
specific: sum of domestic and travel-
related transmission: λdom,a(t)+ λtrav(t)








Srinivasa Rao et al. [18]
b – birth rate Sex and year dependent;
age group <1 only
Estimated from data held by
Statistics Netherlands
η – net rate of demographic
factors (mortality, immigration, emigration)
Sex, age-group,
and year dependent
Estimated from data held by
Statistics Netherlands
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of life lost due to disability (YLD). YLD is computed as
the product of the disability weight and duration of ill-
ness associated with a specific health outcome, accumu-
lated over the number of incident cases in all health
outcomes including and leading from acute infection
(for more details see Mangen, Plass, Havelaar, Gibbons,
Cassini, Mühlberger, van Lier, Haagsma, Brooke, Lai,
et al: The pathogen- and incidence-based DALY approach:
a new methodology for estimating the burden of infec-
tious diseases in Europe, Submitted). The disability weight
for acute infection was estimated as the weighted average
of the disability weights associated with three severity
levels (hospitalised, visiting a GP, and not visiting a GP).
[7] YLL is calculated as the number of deaths causally re-
lated to development of a particular health outcome
multiplied by the life expectancy at the age of death,
summed over all health outcomes.
Uncertainty in the model-generated incidence time-
series was estimated as in Haagsma et al. [22] by assuming
that the simulated annual number of cases is produced by
a Poisson process; thus variability can be expressed by a
Gamma distribution (with parameters shape = mean sim-
ulated annual number of cases, scale = 1) and the range of
uncertainty by the 5th and 95th percentiles of this
distribution. Confidence intervals were then constructed
around DALYs using Latin hypercube sampling methods
[23]. Demographic and transmission dynamic models
were implemented using R statistical software [24].
Scenario analyses
Five scenarios corresponding to various FOI patterns
were investigated. In the baseline scenario, an exponen-
tially decreasing FOI over time of 5% per year, but
constant across sex- and age-groups was implemented
by treating the transmission rate parameters βa as
time-varying, by multiplying the baseline value by exp
(δ * (t – 2000)), where δ is −0.05 and t is year of simula-
tion. The value for δ is consistent with the hypothesised
decline in Europe since the end of the Second World
War [3] and the average 4.5% decline in FOI reported
for the USA [25] throughout the 20th century. Scenario
2 examined the effect on disease burden in the case of a
constant transmission rate over time, to isolate the im-
pact of the annual 5% decrease assumed in the baseline
scenario, Scenarios 3–5 investigated the impact of large
point outbreaks occurring in two different years (2015
and 2025) during the simulation period, by setting the
transmission rate to three times the baseline value dur-
ing a single calendar year. Scenario 3 simulated an out-
break in primary school-aged children 5–9 years old, the
age group with largest proportion (33%) of notified cases
in the Netherlands in the period 1993–1997 [26]; β was
increased only for this age-group. In Scenario 4, an out-
break due to sexual transmission within MSM was
simulated, by confining the three-fold increased trans-
mission rate to men between 25–44 years of age
(roughly corresponding to the age range of 25–48 years
represented by a cluster of 29 HAV cases in MSM
reported in Rotterdam in 1998 [27]). Scenario 5 simu-
lated a potential outbreak in an old peoples’ home (po-
tentially attributable to a foodborne source of infection),
by restricting the three-fold increased β to persons aged
80 years and over. To adjust for differences in subpopu-
lation sizes, the standardised measure DALYs per
100,000 was also calculated for each scenario.
Results
Transmission dynamics
The model (baseline scenario) produced a shift in the
age distribution of immunity over time, as shown by
the projected seroprevalence according to age group
(Figure 2); immunity (the proportion immune) decreased
for all age groups over the simulation period (Figure 2).
The estimated overall number of new infections in the
year 2000 was 1,547, corresponding to an estimated inci-
dence of 9.8 per 100,000 population. The age-group with
the largest proportion of new infections (27.8%) was
5–9 years. The age distribution was less skewed by the
end of the simulation period; in 2030 the largest propor-
tion of new infections (10.6%) was also predicted to
occur in the 5–9 years age-group, with relatively more
Figure 2 Estimated HAV seroprevalence by age group in 2000
and 2030 (upper panel); the estimated proportion of the
population with HAV immunity between 2000 and 2030 for
selected age groups (lower panel).
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infections occurring in the older age groups compared
with 2000 (Figure 3). 23.5% of all new infections in 2030
were represented by persons 55 years and older, compared
with 5.5% in 2000. Age-group specific incidence estimated
for the years 2000 and 2030 is provided in Table 2.
Population dynamics
The demographic model projected steady growth in the
size of the Netherlands population, from 15.9 million
persons in 2000 to 17.6 million in 2030, with an increase
in the proportion of 55–74 year-olds and 75-plussers
from 18% and 6%, respectively, to 25% and 23%, and a
decrease in the proportion of 35–54 year olds, from 30%
to 23%, over the same period.
Estimated future burden from HAV
A five-fold decrease in the overall annual disease burden
of HAV in the Netherlands was predicted over the
simulation period, from 310 DALYs (95% CI: 296–326;
YLL = 231, 95% CI: 221–244) in the year 2000 to 67
DALYs (95% CI: 60–75; YLL = 54, 95% CI: 48–60) in
2030. This decrease was mostly confined to persons
younger than 55 years (Figure 3).
Although differences in estimated burden between dy-
namic compared with steady-state demographic assump-
tions were small for the first year of the simulation
period (Figure 4), there were larger differences (fewer
predicted DALYs for the static demographic model)
30 years later, seen in the age group 55–59 and older.
By subtracting the DALYs for infection in 2030 that
were estimated assuming a static demography from the
DALYs estimated under the baseline simulation (i.e., dy-
namic demography and cohort effect), and similarly the
DALYs estimated from a simulation with no cohort ef-
fect (i.e., the percentage with natural immunity in 2000
was assumed constant over all age groups, at the mean
value of 36.5%), the effects of population change and
the replacement of immune cohorts can be separated
(Figure 4). Regarding burden projections for 2030, a
slightly larger impact on burden was associated with the
cohort effect (a difference of 17 DALYs, compared with
12 DALYs attributed to demographic change).
The results of the scenario analyses are shown in
Figure 5. In Scenario 2, in which a constant transmission
rate over time was assumed, there was an increase in
DALYs over the simulation period, from 314 in 2000 to
1,083 in 2030. In the three outbreak scenarios, a greater
total disease burden was forecast for the 5–9 years sce-
nario (279 DALYs in 2015–16; 0.83 DALYs/100,000) than
for the 25–44 year-old males scenario (e.g., 265 DALYs in
2015–16; 0.78 DALYs/100,000) or the 80+ scenario (239
DALYs in 2015–16; 0.71 DALYs/100,000). The same pat-
tern was observed, although with lower predicted disease
burdens, if the outbreak was simulated in 2025.
Discussion
The modelled burden of HAV in the Netherlands is
projected to drop in the coming decades, from 310
Figure 3 Estimated age-group specific burden of HAV. Acute infections occurring in the years 2000 and 2030 are compared, and are plotted
separately for males (upper panel) and females (lower panel). Vertical lines indicate 95% confidence intervals.
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DALYs per year in 2000 to about one-fifth this number
in 2030. This is attributable to the exponentially decreas-
ing FOI trend assumed in the baseline simulation. How-
ever, population ageing and consequent replacement of
immune birth cohorts by cohorts with low natural im-
munity, and the relative increase of the size of the
elderly population (for whom the risk of developing
symptomatic infection and associated morbidity and
mortality is greatest), had a compensatory effect with re-
spect to the estimated future burden. A greater propor-
tion of new HAV infections, and a consequent relatively
stable level of DALYs over time, was projected for the
older (55+ years) age-groups.
Incorporation of a realistic model of demographic
change was influential. The difference between assump-
tions of a static and dynamic demography with respect
to incidence was visible in the 55+ years age-groups.
The age distribution of new infections in 2030 was
shifted from persons aged 55+ years to the <55 years age
groups in the static model variant, because there is a lar-
ger proportion of the population represented by those
under 55 years in the static compared with the dynamic
demographic model. Consistent with this, in the dy-
namic demography (baseline) model the drop in DALYs
forecast for 2030 was mostly localised to persons under
55 years of age.
The greater total burden forecast for the dynamic
compared with the static demography is due to the in-
creasing proportion of the population represented by the
Table 2 Modelled incidence (acute infections per
100,000) by age-group in the years 2000 and 2030




<1 5.1 (2.5–7.9) 1.8 (0.48–3.1)
1-4 24.4 (21.1–27.6) 2.1 (1.2–3.0)
5-9 43.1 (39.3–47.1) 2.8 (1.9–3.8)
10-14 29.9 (26.7–33.1) 2.4 (1.5–3.2)
15-19 13.0 (10.7–15.2) 1.8 (1.0–2.5)
20-24 4.8 ( 3.6–6.0) 1.5 (0.89–2.2)
25-29 4.7 (3.6–5.9) 1.6 (0.93–2.2)
30-34 4.8 (3.7–5.8) 1.6 (0.89–2.2)
35-39 8.5 (7.1–9.9) 1.7 (1.1–2.4)
40-44 5.5 (4.3–6.7) 1.6 (0.97–2.3)
45-49 4.8 (3.7–6.0) 1.6 (0.90–2.2)
50-54 3.5 (2.5–4.4) 1.5 (0.79–2.1)
55-59 2.3 (1.4–3.3) 1.4 (0.79–2.0)
60-64 2.8 (1.7–3.9) 1.4 (0.80–1.9)
65-69 3.4 (2.1–4.6) 1.1 (0.59–1.6)
70-74 2.3 (1.2–3.4) 0.88 (0.39–1.3)
75-79 1.8 (0.87–2.9) 0.72 (0.27–1.2)
80-84 1.9 (0.68–3.2) 0.50 (0.15–0.87)
85+ 1.9 (0.56 –3.2) 0.34 (0.08–0.60)
Figure 4 Comparison of assumptions with respect to the dynamic modelling of demography and the cohort effect. The estimated
annual burden of HAV in the Netherlands (in DALYs per year) for acute infections occurring in the years 2000 (upper panel) and 2030 (lower
panel) is shown, according to three model variants: (i) dynamic demography and cohort effect; (ii) steady state demography and cohort effect,
(iii) dynamic demography and no cohort effect. Note the difference in scale on y-axis.
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elderly over time, and to the loss of natural immunity in
the older cohorts. Through comparison of the projected
total disease burden in the baseline simulation with the
results of the simulation with no cohort effect (in which
the initial proportion immune was assumed constant
across all age-groups), the cohort effect had a slightly
larger impact on the estimated disease burden for infec-
tions occurring in 2030 than did the ageing and growth
of the population.
This baseline scenario assumed a steadily decreasing
FOI over the simulation period, in which the decline in
FOI associated with improvements in socio-economic
conditions following the end of the Second World War
was assumed to continue to drop at the rate of 5% per
year. If a constant FOI over time is assumed instead
(Scenario 2), then an increasing estimated future burden
between 2000 and 2030 is forecast (Figure 5).
The impact of the projected increase in population-
wide susceptibility due to the loss of immune cohorts
was explored in three large outbreak scenarios. Simula-
tion of an outbreak among the elderly (80+ years) had
the least impact in terms of burden in the total popula-
tion (239 DALYs in 2015–16). An outbreak in men aged
25–44 years was predicted to result in a greater total dis-
ease burden (265 DALYs in 2015–16), but a simulated
outbreak in primary school-aged children aged 5–9 years
was associated with the largest estimated burden (279
DALYs in 2015–16). This was not merely due to the
relative size of the population represented by this age-
group, as indicated by the DALYs per 100,000 measure.
Previous studies of the transmission dynamics of HAV
infection have accounted for the cohort/natural immun-
ity replacement effect [18,28]; although these studies
used realistic age-structured models fitted to seropreva-
lence data, they have assumed a steady-state demog-
raphy with predictions for population growth achieved
via rescaling [28]; population ageing was not taken
into account. Strengths of our study are the simula-
tion of demographic change and the estimation of the
separate contributions from ageing and the replace-
ment of naturally immune cohorts to the projected
burden of disease.
There are several limitations to the current study. The
first concerns how realistically the model represents
the current epidemiological situation for HAV in the
Netherlands. We assumed that all immunity in the popu-
lation is naturally acquired; the current evidence points to
a moderate proportion of immunity due to vaccination
(recommended to travellers since 1994); 12.6% of the
Pienter 2005/2006 survey participants had been vaccinated
against HAV [1]. Vaccination is also recommended for
high-risk target groups, namely patients with chronic liver
disease and Turkish and Moroccan children before travel-
ling to their country of origin. MSM are offered an HBV
vaccination and often choose to be vaccinated for HAV as
well. We also assumed a fixed transmission rate for travel-
related infection across age-groups and time, which is a
clear simplification; the oldest age-groups may have a
lower likelihood of travelling to endemic countries, and
travel-related transmission may change over time due to
changes in the frequency of travel to, and vaccination
coverage in, destination countries with endemic HAV.
Thus, modelled incidence may be too low if in the future
there is an increased rate of travel to endemic countries,
and/or prevalence in these countries does not improve. In
recent years there has been a marked rise in the propor-
tion of imported cases (between 31 and 51% of all notified
infections in the period 2007–2010 were acquired outwith
the Netherlands [29]).
A second limitation concerns the adequacy of the
transmission and disease burden models. Age-specific
contact patterns were not incorporated, meaning that
homogenous mixing between age-groups was assumed, a
strong simplification. However, this should not be an
issue, as our main goal was to estimate the HAV disease
burden over time. The proportion of babies born im-
mune was fixed instead of being dependent on the num-
ber of women of child-bearing age; however, because of
the relatively rapid loss of maternal immunity this sim-
plification has a minimal effect. We used a weighted
average of disability weights according to the estimated
Figure 5 HAV burden estimates (aggregating all age-groups) in
five scenarios. The baseline scenario, in which the transmission
rate, βa(t), decreases by 5% per year in all age-groups, is compared
to the situation in which βa is assumed constant over time (upper
panel). Three outbreak scenarios were simulated by a 3-fold greater
βa(t) in the year 2015 or 2025 only, in children aged 5–9 years, men
25–44 years, and elderly persons (80+ years) (lower panel).
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overall distribution of acute illness severity [7], and the
same distribution was assumed for all age groups due to
a lack of relevant data. We have also not modelled inter-
ventions such as liver transplantation which would
reduce the number of fatal cases and thus the YLL com-
ponent of DALYs.
Third, we have not attempted to simulate the effects
of control measures that would come into force should
an outbreak be detected, such as the vaccination of con-
tacts. Our simulations thus represent the extreme situ-
ation in which no intervention takes place.
The scenario in which a constant FOI over time was
simulated is perhaps unrealistic in the context of the
widespread availability of vaccination and effective pub-
lic health education. This scenario was useful, neverthe-
less, for illustrating how, in the absence of reduction in
the transmission rate, the combination of demographic
change and the replacement of naturally immune co-
horts can predict a rising disease burden. However, our
baseline scenario in which we assumed a 5% annual de-
cline in the FOI was realistic; there is evidence that
HAV incidence in the Netherlands, although relatively
stable from the mid-1970s to mid-1990s [26] is now
steadily decreasing. Data on acute HAV cases retrieved
from the Dutch national notification system indicate a
decrease in HAV notifications between 1995 and 2005,
from 6.5 to 1.3 per 100,000 [9]. This likely reflects a
combination of a reduction in importation (affecting
the proportion of travel-related cases, model param-
eter ϕ), possibly attributable to improved vaccination
rates among travellers or to reduced endemicity in the
destination countries (affecting the transmission rate
βtrav) [30].
Conclusions
Universal or targetted HAV vaccination is currently not
economically favourable in the Netherlands [31] due to
the relatively low current disease burden and the high
cost of implemention. Our study suggests that vaccin-
ation may need to be re-evaluated in a few decades’
time, when a large proportion of the population will
consist of susceptible elderly persons – the age-group
with the greatest risk of developing severe complications
following infection. As a means of reducing the future
disease burden, continuing the vaccination of travellers
to endemic countries and of contacts of infected cases is
essential. We suggest that economic evaluations can
benefit from combining models of infection dynamics
and demographic change when forecasting the future
disease burden. The current approach may also be useful
for estimating the burden for other infectious diseases as
herpes zoster, invasive pneumococcal disease, and per-
tussis, especially in an ageing population.
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